Modified dosing schedule efficacy of fosmidomycin and clindamycin against murine malaria Plasmodium berghei
Fosmidomycin and clindamycin target the Plasmodium apicoplast. Combination clinical trials have produced mixed results with the primary problem being the recrudescent infection frequency by day 28. Given that antibiotic efficacy against bacterial infections often depends on the constant drug presenc...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | International Journal for Parasitology: Drugs and Drug Resistance |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211320724000587 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849763654949404672 |
|---|---|
| author | Leah A. Walker Vision Bagonza Bryce Bobb David J. Sullivan |
| author_facet | Leah A. Walker Vision Bagonza Bryce Bobb David J. Sullivan |
| author_sort | Leah A. Walker |
| collection | DOAJ |
| description | Fosmidomycin and clindamycin target the Plasmodium apicoplast. Combination clinical trials have produced mixed results with the primary problem being the recrudescent infection frequency by day 28. Given that antibiotic efficacy against bacterial infections often depends on the constant drug presence over several days, we hypothesized that the antimalarial blood or liver stage efficacy of fosmidomycin and clindamycin could be improved by implementing a more frequent dosing schedule. A blood stage murine malaria P. berghei GFP-luciferase low and high parasitemia model was implemented to follow pharmacodynamics and cure for modified dose, schedule and duration of individual and combination fosmidomycin and clindamycin. P. berghei sporozoites were used to investigate fosmidomycin during the 48 h murine liver stage. Here we observed that the same total dose of fosmidomycin and clindamycin, alone and in combination, are more efficacious when scheduled in smaller, more frequent doses. Fosmidomycin added measurably small additional killing in combination with clindamycin. Despite dosing every 6 h during liver stages, fosmidomycin was inhibitory, but noncurative even with addition of atorvastatin to decrease hepatocyte production of mevalonate. We have also demonstrated in vitro efficacy of fosmidomycin and clindamycin against P. falciparum C580Y with IC50s similar to those for drug sensitive P. falciparum. The dosing schedule of quinoline and artemisinin partner drugs fosmidomycin or clindamycin targeting the apicoplast should maximize time above minimum inhibitory concentration. |
| format | Article |
| id | doaj-art-3db66da28dea4e90936bcabbd63ff2d8 |
| institution | DOAJ |
| issn | 2211-3207 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal for Parasitology: Drugs and Drug Resistance |
| spelling | doaj-art-3db66da28dea4e90936bcabbd63ff2d82025-08-20T03:05:21ZengElsevierInternational Journal for Parasitology: Drugs and Drug Resistance2211-32072025-04-012710057710.1016/j.ijpddr.2024.100577Modified dosing schedule efficacy of fosmidomycin and clindamycin against murine malaria Plasmodium bergheiLeah A. Walker0Vision Bagonza1Bryce Bobb2David J. Sullivan3W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD, 21210, USAW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD, 21210, USAW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD, 21210, USACorresponding author. Johns Hopkins Bloomberg School of Public Health. 615 North Wolfe Street, Baltimore, MD 21205, USA.; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD, 21210, USAFosmidomycin and clindamycin target the Plasmodium apicoplast. Combination clinical trials have produced mixed results with the primary problem being the recrudescent infection frequency by day 28. Given that antibiotic efficacy against bacterial infections often depends on the constant drug presence over several days, we hypothesized that the antimalarial blood or liver stage efficacy of fosmidomycin and clindamycin could be improved by implementing a more frequent dosing schedule. A blood stage murine malaria P. berghei GFP-luciferase low and high parasitemia model was implemented to follow pharmacodynamics and cure for modified dose, schedule and duration of individual and combination fosmidomycin and clindamycin. P. berghei sporozoites were used to investigate fosmidomycin during the 48 h murine liver stage. Here we observed that the same total dose of fosmidomycin and clindamycin, alone and in combination, are more efficacious when scheduled in smaller, more frequent doses. Fosmidomycin added measurably small additional killing in combination with clindamycin. Despite dosing every 6 h during liver stages, fosmidomycin was inhibitory, but noncurative even with addition of atorvastatin to decrease hepatocyte production of mevalonate. We have also demonstrated in vitro efficacy of fosmidomycin and clindamycin against P. falciparum C580Y with IC50s similar to those for drug sensitive P. falciparum. The dosing schedule of quinoline and artemisinin partner drugs fosmidomycin or clindamycin targeting the apicoplast should maximize time above minimum inhibitory concentration.http://www.sciencedirect.com/science/article/pii/S2211320724000587ClindamycinFosmidomycinPharmacodynamicsApicoplastMurine malariaPlasmodium berghei |
| spellingShingle | Leah A. Walker Vision Bagonza Bryce Bobb David J. Sullivan Modified dosing schedule efficacy of fosmidomycin and clindamycin against murine malaria Plasmodium berghei International Journal for Parasitology: Drugs and Drug Resistance Clindamycin Fosmidomycin Pharmacodynamics Apicoplast Murine malaria Plasmodium berghei |
| title | Modified dosing schedule efficacy of fosmidomycin and clindamycin against murine malaria Plasmodium berghei |
| title_full | Modified dosing schedule efficacy of fosmidomycin and clindamycin against murine malaria Plasmodium berghei |
| title_fullStr | Modified dosing schedule efficacy of fosmidomycin and clindamycin against murine malaria Plasmodium berghei |
| title_full_unstemmed | Modified dosing schedule efficacy of fosmidomycin and clindamycin against murine malaria Plasmodium berghei |
| title_short | Modified dosing schedule efficacy of fosmidomycin and clindamycin against murine malaria Plasmodium berghei |
| title_sort | modified dosing schedule efficacy of fosmidomycin and clindamycin against murine malaria plasmodium berghei |
| topic | Clindamycin Fosmidomycin Pharmacodynamics Apicoplast Murine malaria Plasmodium berghei |
| url | http://www.sciencedirect.com/science/article/pii/S2211320724000587 |
| work_keys_str_mv | AT leahawalker modifieddosingscheduleefficacyoffosmidomycinandclindamycinagainstmurinemalariaplasmodiumberghei AT visionbagonza modifieddosingscheduleefficacyoffosmidomycinandclindamycinagainstmurinemalariaplasmodiumberghei AT brycebobb modifieddosingscheduleefficacyoffosmidomycinandclindamycinagainstmurinemalariaplasmodiumberghei AT davidjsullivan modifieddosingscheduleefficacyoffosmidomycinandclindamycinagainstmurinemalariaplasmodiumberghei |